Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion–Positive Lung CancerJustin F. Gainor, Ted W. Johnson, Ramin Sakhtemani et al.|Clinical Cancer Research|2021Cited by 137
Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLCW. Marston Linehan, Gregory J. Riely, Viola W. Zhu et al.|Journal of Thoracic Oncology|2018Cited by 82
Durable Response to Dabrafenib Combined With Trametinib in a Patient With NSCLC Harboring a BRAF G469A MutationIbiayi Dagogo‐Jack|Journal of Thoracic Oncology|2020Cited by 28